keyword
MENU ▼
Read by QxMD icon Read
search

DLBCL

keyword
https://www.readbyqxmd.com/read/29345210/the-impact-of-time-from-diagnosis-to-treatment-in-diffuse-large-b-cell-lymphoma
#1
Colin Phipps, Yuh Shan Lee, Hao Ying, Chandramouli Nagarajan, Nicholas Grigoropoulos, Yunxin Chen, Tiffany Tang, Alan Z Goh, Aditi Ghosh, Heng Joo Ng, Sathish Gopalakrishnan, Yvonne Loh, Soon Thye Lim, William Hwang, Daryl Tan, Yeow Tee Goh
Diffuse large B-cell lymphoma (DLBCL) is a high-grade lymphoma that requires treatment. We retrospectively analyzed the impact of time from diagnosis-to-treatment (TDT) on progression-free survival (PFS) and overall survival (OS) in 581 R-CHOP-treated patients. TDT was defined as the interval between diagnostic biopsy date and day 1 R-CHOP. Cox regression showed stage 3-4 disease (p = .01) and longer TDT (HR 1.13, p =.031) were associated with shorter OS. Eastern Cooperative Oncology Group ≥2 (p = ...
January 18, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29344120/interim-18f-fdg-pet-ct-improves-the-prognostic-value-of-s-ipi-r-ipi-and-nccn-ipi-in-patients-with-diffuse-large-b-cell-lymphoma
#2
Maoqing Jiang, Ping Chen, Xinzhong Ruan, Xianwang Ye, Yuning Pan, Jie Zhang, Qiuli Huang, Wenlan Zhou, Hubing Wu, Quanshi Wang
The current study aimed to explore whether the efficiency of the standard International Prognostic Index (S-IPI), revised-IPI (R-IPI) and enhanced-IPI (NCCN-IPI) in evaluating the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) may be improved by interim 18F-FDG PET/CT. A total of 185 patients with newly diagnosed DLBCL were enrolled in the current study. All patients underwent interim PET/CT following the 4th cycle of chemotherapy. Patients were divided into different risk groups using S-IPI, R-IPI and NCCN-IPI and further subdivided into risk groups using interim PET/CT...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29340126/hepatosplenic-gamma-delta-t-cell-lymphoma-hsgdtcl-two-rare-case-reports-from-western-india
#3
Irappa Madabhavi, Gaurang Modi, Harsha Panchal, Apurva Patel, Swaroop Revannasiddaiah, Asha Anand, Sonia Parikh, Kshitij Joshi, Malay Sarkar
Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid malignancies, accounting for approximately 10-15% of all non-Hodgkin's lymphomas. Hepatosplenic T-cell lymphoma (HSGDTCL) is a rare entity, which is characterized by primary extra nodal disease with typical sinusoidal or sinusal infiltration of the liver and the spleen, respectively by expression of the T-cell receptor γδ chain, and by a number of other frequent clinicopathologic features, including aggressive course of disease...
October 1, 2017: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/29340082/reciprocal-sensitivity-of-diffuse-large-b-cell-lymphoma-cells-to-bcl-2-inhibitors-bird-2-versus-venetoclax
#4
Tamara Vervloessem, Haidar Akl, Thomas Tousseyn, Humbert De Smedt, Jan B Parys, Geert Bultynck
Bcl-2 is often upregulated in cancers to neutralize the BH3-only protein Bim at the mitochondria. BH3 mimetics (e.g. ABT-199 (venetoclax)) kill cancer cells by targeting Bcl-2's hydrophobic cleft and disrupting Bcl-2/Bim complexes. Some cancers with elevated Bcl-2 display poor responses towards BH3 mimetics, suggesting an additional function for anti-apoptotic Bcl-2 in these cancers. Indeed, Bcl-2 via its BH4 domain prevents cytotoxic Ca2+ release from the endoplasmic reticulum (ER) by directly inhibiting the inositol 1,4,5-trisphosphate receptor (IP3R)...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29338665/adjuvant-radiotherapy-in-patients-with-diffuse-large-b-cell-lymphoma-in-advanced-stage-iii-iv-improves-the-outcome-in-the-rituximab-era
#5
Agustin Avilès, Maria-Jesus Nambo, Angel Calva, Natividad Neri, Sergio Cleto, Luis Silva
OBJECTIVES: To assess the efficacy and toxicity of adjuvant radiotherapy (RT) in patients with diffuse large B-cell lymphoma (DLBCL) and nodal bulky disease, on complete response, after six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), we began an open-label clinical trial in a large cohort with longer follow-up to evaluate the outcome measured from progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: Between 2006 and 2010, 258 consecutive patients with DLBCL and nodal bulky disease (tumor mass >10 cm) were randomly assigned to receive either RT (involved field, 30 Gy) (127 patients) or no (control group) (131 patients)...
January 17, 2018: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/29337296/computer-analysis-of-histopathological-images-for-tumor-grading
#6
Wlodzimierz Klonowski, Anna Korzynska, Ryszard Gomolka
We developed a new method that enables automatic and rapid assessment of a tumor's proliferative index from immunohistochemically (IHC) stained microscopic images. This method is simple, rapid, and does not require the time consuming manual step of selecting areas of interest or the need for computationally complicated detection of hot-spots, both of which attempt to emulate a pathologist's way of estimating a proliferation index. We apply our method to a set of diffuse large B-cell lymphoma (DLBCL) slide images...
January 16, 2018: Physiological Measurement
https://www.readbyqxmd.com/read/29337112/molecular-heterogeneity-in-diffuse-large-b-cell-lymphoma-and-its-implications-in-clinical-diagnosis-and-treatment
#7
REVIEW
Lingchuan Guo, Pei Lin, Hui Xiong, Shichun Tu, Gang Chen
Over half of patients with diffuse large B-cell lymphoma (DLBCL) can be cured by standard R-CHOP treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). However, the remaining patients are refractory and ultimately succumb to progressive or relapsed disease. During the past decade, there has been significant progress in the understanding of molecular mechanisms in DLBCL, largely owing to collaborative efforts in large-scale gene expression profiling and deep sequencing, which have identified genetic alterations critical in lymphomagenesis through activation of key signaling transduction pathways in DLBCL...
January 11, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29335581/role-of-hypoxia-in-diffuse-large-b-cell-lymphoma-metabolic-repression-and-selective-translation-of-hk2-facilitates-development-of-dlbcl
#8
Kavita Bhalla, Sausan Jaber, Nanaji Nahid M, Karen Underwood, Afshin Beheshti, Ari Landon, Binny Bhandary, Paul Bastain, Andrew M Evens, John Haley, Brian Polster, Ronald B Gartenhaus
Published molecular profiling studies in patients with lymphoma suggested the influence of hypoxia inducible factor-1 alpha (HIF1α) targets in prognosis of DLBCL. Yet, the role of hypoxia in hematological malignancies remains unclear. We observed that activation of HIF1α resulted in global translation repression during hypoxic stress in DLBCL. Protein translation efficiency as measured using 35S-labeled methionine incorporation revealed a ≥50% reduction in translation upon activation of HIF1α. Importantly, translation was not completely inhibited and expression of clinically correlated hypoxia targets such as GLUT1, HK2, and CYT-C was found to be refractory to translational repression under hypoxia in DLBCL cells...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29335468/aicda-drives-epigenetic-heterogeneity-and-accelerates-germinal-center-derived-lymphomagenesis
#9
Matt Teater, Pilar M Dominguez, David Redmond, Zhengming Chen, Daisuke Ennishi, David W Scott, Luisa Cimmino, Paola Ghione, Jayanta Chaudhuri, Randy D Gascoyne, Iannis Aifantis, Giorgio Inghirami, Olivier Elemento, Ari Melnick, Rita Shaknovich
Epigenetic heterogeneity is emerging as a feature of tumors. In diffuse large B-cell lymphoma (DLBCL), increased cytosine methylation heterogeneity is associated with poor clinical outcome, yet the underlying mechanisms remain unclear. Activation-induced cytidine deaminase (AICDA), an enzyme that mediates affinity maturation and facilitates DNA demethylation in germinal center (GC) B cells, is required for DLBCL pathogenesis and linked to inferior outcome. Here we show that AICDA overexpression causes more aggressive disease in BCL2-driven murine lymphomas...
January 15, 2018: Nature Communications
https://www.readbyqxmd.com/read/29333404/relevance-of-prognostic-index-with-%C3%AE-2-microglobulin-for-patients-with-diffuse-large-b-cell-lymphoma-in-the-rituximab-era
#10
Jihoon Kang, Shinkyo Yoon, Cheolwon Suh
Background: The International Prognostic Index (IPI) has been a useful tool for predicting the prognosis of aggressive non-Hodgkin lymphoma in the last 20 years. Herein, we aimed to develop a new prognostic model for diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Methods: Between March 2004 and June 2012, patients with DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy regimen were identified in the database of the Asan Medical Center (AMC) Lymphoma Registry...
December 2017: Blood Research
https://www.readbyqxmd.com/read/29333016/clinicopathological-features-and-outcomes-in-primary-central-nervous-system-lymphoma-a-10-year-experience
#11
Chaitanya Krishna Puligundla, Stalin Bala, Ashok Kumar Karnam, Sadashivudu Gundeti, Tara Roshni Paul, Megha S Uppin, Lakshmi Srinivas Maddali
Context: Primary central nervous system lymphoma (PCNSL) is a variant of extranodal lymphoma, accounting for 4% of primary central nervous system tumors. PCNSL was more common in immunocompetent individuals. International Extranodal Lymphoma Study Group (IELSG) scoring was used for prognostication. High-dose methotrexate regimens along with radiotherapy improved outcomes in PCNSL. Aims: The aim of this study is to analyze the clinical and pathological features, progression-free survival (PFS), and overall survival (OS) in patients with PCNSL...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29326347/limited-stage-dlbcl-it-s-patient-selection
#12
Daniel O Persky
No abstract text is available yet for this article.
January 11, 2018: Blood
https://www.readbyqxmd.com/read/29325396/treatment-results-of-radiotherapy-following-chop-or-r-chop-in-limited-stage-head-and-neck-diffuse-large-b-cell-lymphoma-a-single-institutional-experience
#13
Jae-Uk Jeong, Woong-Ki Chung, Taek-Keun Nam, Deok-Hwan Yang, Sung-Ja Ahn, Ju-Young Song, Mee Sun Yoon, Yong-Hyeob Kim
PURPOSE: This study evaluated outcomes of radiotherapy (RT) after chemotherapy in limited-stage head-and-neck diffuse large B-cell lymphoma (DLBCL). MATERIALS AND METHODS: Eighty patients who were treated for limited-stage head-and-neck DLBCL with CHOP (n = 43) or R-CHOP (n = 37), were analyzed. After chemotherapy, RT was administered to the extended field (n = 60) or the involved field (n = 16), or the involved site (n = 4). The median dose of RT ranged from 36 Gy in case of those with a complete response, to 45-60 Gy in those with a partial response...
December 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/29325248/-survival-of-patients-with-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-impact-of-gene-aberrations-and-protein-overexpression-of-bcl-2-and-c-myc-and-selection-of-chemotherapy-regimens
#14
W J Yin, X Zhu, H Y Yang, W Y Sun, M J Wu
Objective: To investigate the impact of clinicopathological features, gene rearrangements and protein expression of bcl-6, bcl-2, C-MYC and chemotherapy regime on the prognosis of patients with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL). Methods: Thirty-three cases of PCNS-DLBCL diagnosed from January 2006 to December 2016 at Zhejiang Cancer Hospital were collected. The expression of CD10, bcl-6, bcl-2, MUM1 and MYC were detected by immunohistochemical staining (IHC). The presence of EB virus was detected by in situ hybridization(EBER)...
January 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29325247/-impact-of-prdm1-gene-inactivation-on-c-myc-regulation-in-diffuse-large-b-cell-lymphoma
#15
X Y Zhang, Z P Ma, W L Cui, X L Pang, R Chen, L Wang, W Zhang, X X Li
Objective: To investigate the role of PRDM1 gene inactivaion in the regulation of C-MYC in diffuse large B-cell lymphoma (DLBCL), and to explore the correlation of its immunophenotype and prognosis. Methods: 100 cases paraffin-embedded DLBCL tissues were collected from January 2009 to December 2015 at the First Affiliated Hospital of Xinjiang Medical University along with 20 cases of reactive proliferative lymph nodes as control. Immunohistochemical methods were used to detect the expression of CD20, CD10, MUM1, Ki-67, bcl-6, PRDM1/Blimp1, C-MYC and PAX5 protein...
January 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29322833/primary-genitourinary-lymphoma-on-fdg-pet
#16
Nikita Naik, Michael Lin, Peter Lin
Primary extra nodal lymphomatous involvement of the genitourinary tract is rare and secondary extra-nodal involvement in disseminated disease occurs more frequently. Imaging of metabolic activity with 2-[fluorine-18] fluoro-2-deoxy-d-glucose (FDG) used in positron emission tomography (PET) facilitates the identification of these extra-nodal sites of disease, particularly in the absence of structural lesions on conventional imaging modalities. Primary extra-nodal lymphoma affecting the genitourinary system is often caused by high-grade Non-Hodgkin's Lymphoma (NHL) with the most common subtype being Diffuse Large B-Cell Lymphoma (DLBCL)...
January 11, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29317552/validation-and-refinement-of-the-age-comorbidities-and-albumin-index-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-an-effective-tool-for-comprehensive-geriatric-assessment
#17
Hui Liu, Chun-Li Zhang, Ru Feng, Jiang-Tao Li, Yuan Tian, Ting Wang
BACKGROUND: We aimed to validate and refine the Age, Comorbidities, and Albumin (ACA) index in elderly Chinese patients with diffuse large B-cell lymphoma (DLBCL) and propose a more effective method for comprehensive geriatric assessment (CGA). MATERIALS AND METHODS: Patients ≥65 years of age who had been diagnosed with de novo DLBCL in the Institute of Hematology, Beijing Hospital, were screened for eligibility (n = 99). RESULTS: Based on the ACA index, 39, 31, 26, and 3 patients were categorized into the "excellent," "good," "moderate," and "poor" groups, respectively...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29309299/comparison-of-myocyte-enhancer-factor-2b-versus-other-germinal-center-associated-antigens-in-the-differential-diagnosis-of-b-cell-non-hodgkin-lymphomas
#18
Erika M Moore, Steven H Swerdlow, Sarah E Gibson
Myocyte enhancer binding factor 2B (MEF2B) is a transcriptional activator of the BCL6 proto-oncogene in normal germinal center (GC) B-cells. Limited data exists concerning its expression in B-cell lymphomas, and comparison with other GC-associated antigens is lacking. Its role in the differential diagnosis of B-cell lymphomas, particularly in the distinction of follicular lymphoma (FL) versus marginal zone lymphoma (MZL), remains to be determined. We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL...
January 5, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29297513/treatment-and-relative-survival-in-very-elderly-patients-with-dlbcl-in-the-netherlands-a-population-based-study-1989-to-2015
#19
COMMENT
Avinash G Dinmohamed, Djamila E Issa, Marjolein W M van der Poel, Harry C Schouten, Pieternella J Lugtenburg, Martine E D Chamuleau, Sonja Zweegman, Otto Visser
No abstract text is available yet for this article.
September 26, 2017: Blood Advances
https://www.readbyqxmd.com/read/29296965/infiltration-of-effector-regulatory-t-cells-predicts-poor-prognosis-of-diffuse-large-b-cell-lymphoma-not-otherwise-specified
#20
Shoko Nakayama, Taiji Yokote, Toshikazu Akioka, Nobuya Hiraoka, Uta Nishiwaki, Takuji Miyoshi, Kazuki Iwaki, Ayami Takayama, Yuki Masuda, Jun Hatooka, Mayumi Fujimoto, Yasuichiro Nishimura, Motomu Tsuji
Regulatory T cells (Tregs) specifically express the transcription factor forkhead box P3 (FOXP3) and contribute to tumor progression. FOXP3-positive cells have been recently proven to be heterogeneous in phenotype and function, including effector Tregs (eTregs), naïve Tregs, and non-Tregs, which harbor no suppressive function. Therefore, it is crucial to investigate the "true Treg (eTreg)" population, rather than the entire FOXP3 population, with regards to their effect on tumor immunity. In particular, in diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), FOXP3-positive cells correlated with a better prognosis...
March 14, 2017: Blood Advances
keyword
keyword
98
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"